K-Pharma and Biotech Expand AI-Based New Drug Design and Disease Prediction

Korean pharma and biotech firms are rapidly expanding AI from drug design to disease prediction and clinical evaluation.

Hanmi Pharm is using an AI platform to design obesity drug candidates now in phase 1 trials, while GC Biopharma is developing a model to predict the long-term progression of hemophilia arthropathy.

SK Biopharm is researching EEG-based seizure detection and prediction AI, and Connective is quantifying treatment effects in osteoarthritis trials with X-ray AI metrics.

As AI adoption grows, it could improve research efficiency and enable more personalized care, but clinical validation and regulatory approval remain key hurdles.